Medicaid Formulary Decisions: Shift To MCOs May Limit Pharma Input – Study
Executive Summary
Drug firms may find it harder to contribute to Medicaid formulary decisions in the coming years as state programs increasingly turn to managed care organizations to handle their pharmacy benefits, according to a recent research report by Avalere Health and the Kaiser Commission on Medicaid and the Uninsured.
You may also be interested in...
New York Medicaid Drug Benefit “Carved In” To Managed Care Program
Prescription drug coverage under New York Medicaid will be shifted to its managed care program, effective Oct. 1, under the fiscal 2011-2012 budget approved by the state legislature.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.
Biden vs Trump On Drug Pricing And Unfinished Business
While more significant reforms are less likely under a second Biden term unless Democrats control both chambers of Congress, former President Trump could look to put his stamp on drug pricing reform by resurrecting one of his former policies involving international reference pricing and Medicare Part B drugs.